Management of glaucoma as a neurodegenerative disease

Neurodegener Dis Manag. 2017 Apr;7(2):157-172. doi: 10.2217/nmt-2017-0004. Epub 2017 May 22.

Abstract

Glaucoma is a neurodegenerative disease with an estimated prevalence of 60 million people, and the most common cause of irreversible blindness worldwide. The mainstay of treatment has been aimed at lowering intraocular pressure, currently the only modifiable risk factor. Unfortunately, despite adequate pressure control, many patients go on to suffer irreversible visual loss. We first briefly examine currently established intraocular pressure lowering-treatments, with a discussion of their roles in neuroprotection as demonstrated by both animal and clinical studies. The review then examines currently available intraocular pressure independent agents that have shown promise for possessing neuroprotective effects in the management of glaucoma. Finally, we explore potential future treatments such as immune-modulation, stem cell therapy and neural regeneration as they may provide further protection against the neurodegenerative processes involved in glaucomatous optic neuropathy.

Keywords: glaucoma; neuromodulation; neuroprotection; stem cell therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Glaucoma / drug therapy*
  • Humans
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / therapy
  • Neuroprotective Agents / therapeutic use*
  • Stem Cell Transplantation

Substances

  • Neuroprotective Agents